XBP1 and cancer: Dual inhibitors, such as MKC-3946 and GSK2850163, are also effective in cancer treatment by modulating kinase-driven XBP1 splicing and RNase-driven mRNA decay, offering therapeutic potential for chronic ER stress-related diseases.